These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11900314)

  • 21. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY; Tsai YW; Huang WF
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.
    Brownstein JS; Sordo M; Kohane IS; Mandl KD
    PLoS One; 2007 Sep; 2(9):e840. PubMed ID: 17786211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy.
    Knowles S; Shapiro L; Shear NH
    Drug Saf; 2001; 24(4):239-47. PubMed ID: 11330653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.
    Habeeb AG; Praveen Rao PN; Knaus EE
    J Med Chem; 2001 Aug; 44(18):3039-42. PubMed ID: 11520213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Safety of celecoxib and rofecoxib: a critical overview].
    Alegre Del Rey EJ
    Med Clin (Barc); 2002 Feb; 118(6):237. PubMed ID: 11864549
    [No Abstract]   [Full Text] [Related]  

  • 27. Urticaria and angioedema from cyclooxygenase-2 inhibitors.
    Kelkar PS; Butterfield JH; Teaford HG
    J Rheumatol; 2001 Nov; 28(11):2553-4. PubMed ID: 11708434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
    Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study.
    Shapiro LE; Knowles SR; Weber E; Neuman MG; Shear NH
    Drug Saf; 2003; 26(3):187-95. PubMed ID: 12580647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
    Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports.
    Sanchez-Matienzo D; Arana A; Castellsague J; Perez-Gutthann S
    Clin Ther; 2006 Aug; 28(8):1123-1132. PubMed ID: 16982289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Celecoxib and rofecoxib.
    Brinker AD; Bonnel RA; Feight AG; Nourjah P
    J Am Dent Assoc; 2001 Nov; 132(11):1502, 1504. PubMed ID: 11806062
    [No Abstract]   [Full Text] [Related]  

  • 35. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
    Cutts C; LaCaze A; Tett S
    Br J Clin Pharmacol; 2002 Nov; 54(5):522-7. PubMed ID: 12445032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Celecoxib- and rofecoxib-induced delirium.
    Macknight C; Rojas-Fernandez CH
    J Neuropsychiatry Clin Neurosci; 2001; 13(2):305-6. PubMed ID: 11449042
    [No Abstract]   [Full Text] [Related]  

  • 37. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between COX-2 specific inhibitors and hypertension.
    Solomon DH; Schneeweiss S; Levin R; Avorn J
    Hypertension; 2004 Aug; 44(2):140-5. PubMed ID: 15226279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
    Graham GG; Graham RI; Day RO
    Curr Pharm Des; 2002; 8(12):1063-75. PubMed ID: 11945151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole.
    Fontaine C; Bousquet PJ; Demoly P
    J Allergy Clin Immunol; 2005 Mar; 115(3):633-4. PubMed ID: 15753917
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.